Pennsylvania State University College of Medicine (PSCOM), known simply as Penn State College of Medicine is the medical school of Penn State. While the main Penn State campus is in State College PA, this school is located in Hershey Pennsylvania in order to align with Penn State Milton S. Hershey Medical Center, the medical school’s principal affiliate. The medical school includes 26 basic science and clinical departments and a broad range of clinical programs conducted at its hospital affiliates and numerous ambulatory care sites in the region.
Introduction Aromatase inhibitors (AIs) reduce recurrence and mortality in hormone receptor-positive breast cancer; however, up to 70% of patients discontinue therapy early because of AI-associated arthralgia. Joint pain affects more than half of AI users and can be burdensome among breast cancer survivors. Exercise and education may reduce symptoms and improve adherence, but interventions tailored for older survivors remain limited. Materials and methods We evaluated REJOIN, a remotely delivered exercise and education intervention. In this pilot randomized controlled trial, 24 older breast cancer survivors receiving AI therapy were recruited from two cancer centers and randomized to REJOIN or enhanced standard care. The 16-week intervention included supervised resistance and aerobic exercise, education on AI-related side effects, and self-management strategies. Outcomes included joint pain measured by the Brief Pain Inventory and AI adherence measured by the Morisky-Levine-Green Medication Adherence Scale. Additional measures included accelerometer-assessed physical activity and a geriatric assessment. Results Participants (n = 24) had a mean age of 71.4 years (range 60–88), and more than one-third resided in rural communities. Retention was 80% over 12 months. Comparing REJOIN with standard care, changes from baseline to 4 months were evaluated using Wilcoxon tests and Cohen's d effect sizes. REJOIN showed a moderate reduction in joint pain interference (d = −0.47, p = 0.43). Self-reported AI medication adherence was high at baseline in both groups, limiting the ability to detect meaningful improvement; however, adherence patterns over follow-up favored the intervention group. Feasibility benchmarks were met, including accrual of the target sample, retention of 80% at 12 months, and achievement of the prespecified exercise-adherence benchmark, with 12 of 13 intervention participants (94%) completing the required supervised exercise and coaching sessions. Discussion REJOIN was feasible, safe, and acceptable among breast cancer survivors receiving AI therapy. Its remote delivery and engagement of rural participants suggest potential for dissemination and support progression to a larger efficacy trial.
The practice of using validated rating scales to guide treatment—measurement-based care (MBC) remains underutilized in behavioral health. This study examined the association between real-world MBC implementation, ascertained by measure completion, and emergency department (ED) visits. A retrospective cohort design made use of medical insurance claims data (2015–2023) to examine adult psychiatric outpatients exposed to real-world MBC (“MBC” sample; n = 524); 482 were propensity score-matched to patients who received care as usual (“CAU” sample; n = 964). The index visit was the date of registry enrollment for the MBC sample and the first psychiatric encounter while enrolled for the CAU sample. Time-to-event and negative binomial models were used to estimate hazard ratios (HRs) and incidence rate ratios (IRRs) for ED visits. The overall sample included 1,488 patients (63
Neoadjuvant chemotherapy is standard for stage IB-III triple-negative breast cancer (TNBC), with pathological complete response (pCR) strongly associated with survival. Although escalation with platinum and immune checkpoint inhibitors (ICI) improves pCR and long-term outcomes, patients with pCR in control arms of pivotal trials also show favorable outcomes. Whether the regimen leading to pCR impacts long-term survival is largely unknown. We conducted a systematic review and meta-analysis, searching phase II and III trials including early-stage TNBC patients with pCR. A pooled analysis of Kaplan–Meier-derived individual patient data was performed for event-free survival (EFS) and overall survival (OS), with subgroup analyses by treatment regimens. Of 2830 identified publications, 18 trials comprising 3430 patients were included. Neoadjuvant ICI with chemotherapy improved EFS (HR 0.67; 95
This study examines mental health status of patients with complex hypospadias, which include proximal (penoscrotal, scrotal or perineal) hypospadias or hypospadias of any degree with additional urogenital anomalies. Eligible patients of different ages (24
BACKGROUND AND OBJECTIVE:A Likelihood ratio (LR) is a numerical measure of evidential value. Our objective was to use LRs to express the patient-specific evidential values of medical findings that best differentiate abusive versus non-abusive head trauma (AHT). We hypothesized that the evidential values of patients' AHT-related medical findings would be highly variable. METHODS:We analyzed existing, uniform, prospective, de-identified data regarding 973 acutely head-injured children < 3 years hospitalized for intensive care across 18 sites between 2011 and 2021; applied two different proxies for AHT and non-AHT ground truth; trained and validated statistical models that differentiate AHT versus non-AHT; and analyzed patient-specific LRs in a log10 (LLR) format that facilitated assessment of evidential values (where LLR values > 0 and < 0 supported hypotheses of AHT and non-AHT, respectively). RESULTS:The two best performing statistical models revealed evidential (LLR) values for patient-specific, AHT-related medical findings that varied from modest (-1 to + 1) to relatively large (-2.5 to -1 and + 1 to + 3.5), and values that were misleading (AHT patients with LLR values indicative of non-AHT, and vice versa). A few non-AHT patients presented with misleading evidence that was moderately strong, with LLRs approaching + 3. CONCLUSIONS:Reasonable medical certainty of AHT and non-AHT can be enhanced or limited by the highly variable evidential values of patients' most discriminating medical findings. Physicians can use available LRs to inform their AHT-related diagnostic reasoning, opinions, and testimony.